Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody

@article{Siebert2014FunctionalBF,
  title={Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody},
  author={Nikolai Siebert and Diana Seidel and Christin Eger and Madlen J{\"u}ttner and Holger N Lode},
  journal={PLoS ONE},
  year={2014},
  volume={9}
}
Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option to improve outcome. After establishing a production process in Chinese hamster ovary (CHO) cells, ch14.18/CHO was made available in Europe for clinical trials. Here, we describe validated functional bioassays for the purpose of immune monitoring of these trials and demonstrate GD2-specific immune… 

Figures and Tables from this paper

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
TLDR
Ch14.18/CHO-mediated effects upregulate the inhibitory immune checkpoint PD-1/PD-L1, and combination of ch14.
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
TLDR
A comprehensive imaging evaluation of lesions correlating with histopathological demonstration of naxitamab-induced tissue differentiation suggests an undescribed mechanism of action for anti-GD2 mAbs and highlights the limitations of conventional imaging in the evaluation of anti- GD2 immunotherapy clinical efficacy for HR-NB.
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
TLDR
In-patient functional immunomonitoring is shown to be feasible and valuable in contributing to the understanding of anti-cancer combinatorial treatments such as haplo SCT and antibody immunotherapy.
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
TLDR
Different mAb-based strategies that capitalize on the targeting ability of anti-GD2 mAbs to potentially deliver, as monotherapy, or in combination with other treatments, improved antitumor efficacy are discussed.
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
TLDR
The presence of the activating KIR 2DS2 has a major effect on ADCC levels and survival in NB patients treated by LTI of ch14.18/CHO and may therefore be a useful biomarker in combination with FCGR polymorphisms for Ab-based immunotherapies.
Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
TLDR
Co-expression of the stimulatory cytokine IL-15 enhanced the NB-specific anti-tumor effectivity of a TH-directed vaccination in mice and may provide a novel immunological approach for NB patients.
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
GD2-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD2 antibodies (Ab), such as ch14.18, can induce development of human
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
TLDR
Generation and characterization of a new human/mouse chimeric anti-Id Ab ganglidiximab for active immunotherapy against NB and this Ab may be useful to tailor immune responses to the paratope regions mimicking GD2 overexpressed in NB.
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
TLDR
LTI of ch14.18/CHO induced effector mechanisms over the entire treatment period, and may therefore emerge as the preferred delivery method of anti-GD2 immunotherapy to NB patients.
A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells
TLDR
A novel method for evaluating cytotoxicity, which involves the detection and quantification of dead target cells using flowcytometry, which is expected to become a standard assay for evaluating ADCC activity which will ultimately contribute the clinical development of ADCC dependent-antibody therapies.
...
1
2
3
...

References

SHOWING 1-10 OF 29 REFERENCES
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients
Purpose: This study aimed to assess the safety, pharmacokinetic and activity profiles of the human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 produced in Chinese hamster
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
TLDR
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma.
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1
TLDR
Data demonstrate that C activation is fundamental for rituximab therapeutic activity in vivo, suggesting that its activity is T cell independent.
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
TLDR
The induction of a GD2-specific immune response with ganglidiomab, a new anti-idiotype antibody to anti-GD2 antibodies of the 14.18 family is reported, proving GD2 surrogate function and anti-IDiotype characteristics and demonstrating activity against neuroblastoma.
Disialoganglioside Directed Immunotherapy of Neuroblastoma
TLDR
The advent of highly sensitive and specific molecular assays to measure MRD has confirmed the efficacy anti-GD2 antibody immunotherapy in patients with subclinical disease and will allow further optimization of other anti-MRD therapies.
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
TLDR
Data indicate that during therapy, neuroblastomas can acquire resistance to cytotoxic drugs because of the population expansion of tumor cells possessing stable genetic or epigenetic alterations that confer resistance.
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
  • T. Simon, B. Hero, F. Berthold
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Consolidation treatment of stage 4 neuroblastoma with ch14.18 was associated with considerable but manageable side effects and Multivariate analysis failed to demonstrate an advantage of antibody treatment for EFS and OS.
...
1
2
3
...